Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir

Drug Development and Industrial Pharmacy

Volumn 39, Issue 4, 2013, Pages 508-519

  Seyfoddin, Ali ^a   Al Kassas, Raida ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Acyclovir; Entrapment efficiency; Nanostructured lipid carriers; Ocular bioavailability; Ocular drug delivery system; Solid lipid nanoparticles

Indexed keywords

ACICLOVIR; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CORNEA EDEMA; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; FREEZE DRYING; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; ZETA POTENTIAL;

ACYCLOVIR; ADMINISTRATION, OPHTHALMIC; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CATTLE; CORNEA; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; LIPOSOMES; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE;

EID: 84874502028     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.665460     Document Type: Article

References (71)

1. Nahmias AJ. (1975). Editorials: Herpes simplex virus infection-present status of diagnosis and management. South Med J, 68:1191-1194.
2. Liesegang TJ. (2001). Herpes simplex virus epidemiology and ocular importance. Cornea, 20:1-13. (Pubitemid 32038147)
3. Nesburn AB, Burke RL, Ghiasi H, Slanina S, Bahri S, Wechsler SL. (1994). Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. J Virol, 68:5084-5092. (Pubitemid 24226576)
4. Newell CK, Martin S, Sendele D, Mercadal CM, Rouse BT. (1989). Herpes simplex virus-induced stromal keratitis: role of T-lymphocyte subsets in immunopathology. J Virol, 63:769-775. (Pubitemid 19057244)
5. Darougar S, Hunter PA, Viswalingam M, Gibson JA, Jones BR. (1978). Acute follicular conjunctivitis and keratoconjunctivitis due to herpes simplex virus in London. Br J Ophthalmol, 62:843-849. (Pubitemid 9019024)
6. Smith RE, McDonald HR, Nesburn AB, Minckler DS. (1980). Penetrating keratoplasty: changing indications, 1947 to 1978. Arch Ophthalmol, 98:1226-1229. (Pubitemid 10033716)
7. Nesburn AB. (1983) Report of the corneal disease panel: vision research: a national plan 1983-1987, vol. II, part III. St. Louis.: Te C.V. Mosby Co., in: A.B. Nesburn (Ed.), .
8. Ghera BB, Perret F, Chevalier Y, Parrot-Lopez H. (2009). Novel nanoparticles made from amphiphilic perfuoroalkyl alpha-cyclodextrin derivatives: preparation, characterization and application to the transport of acyclovir. Int J Pharm, 375:155-162.
9. de Vrueh RL, Smith PL, Lee CP. (1998). Transport of L-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2. J Pharmacol Exp Ter, 286:1166-1170. (Pubitemid 29135525)
10. Richards DM, Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. (1983). Acyclovir. A review of its pharmacodynamic properties and therapeutic efcacy. Drugs, 26:378-438.
11. Anand BS, Hill JM, Dey S, Maruyama K, Bhattacharjee PS, Myles ME et al. (2003). In vivo antiviral efcacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. Invest Ophthalmol Vis Sci, 44:2529-2534. (Pubitemid 36618411)
12. Foster CS, Azar DT, Dohlman CH. (2005) Smolin and Toft's the cornea: scientifc foundations and clinical practice, Philadelphia: Lippincott Williams & Wilkins.
13. Zaal M, Opstelten W. (2005) Managing ophthalmic herpes zoster in primary care, BMJ-Bri Med J, 331: 147-151. (Pubitemid 41003176)
14. de Jalón EG, Blanco-Príeto MJ, Ygartua P, Santoyo S. (2003). Increased efcacy of acyclovir-loaded microparticles against herpes simplex virus type 1 in cell culture. Eur J Pharm Biopharm, 56:183-187. (Pubitemid 37072101)
15. Law SL, Huang KJ, Chiang CH. (2000). Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. J Control Release, 63:135-140. (Pubitemid 30046949)
16. Tao Y, Lu Y, Sun Y, Gu B, Lu W, Pan J. (2009). Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability. Int J Pharm, 378:30-36.
17. Majumdar S, Hippalgaonkar K, Repka MA. (2008). Efect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int J Pharm, 348:175-178. (Pubitemid 350266247)
18. Stulzer HK, Lacerda, Tagliari MP, Silva MA, Fávere VT, Laranjeira MC. (2008) Synthesis and characterization of cross-linked malonylchitosan microspheres for controlled release of acyclovir. Carbohydr Polymer, 73: 490-497.
19. Mehnert W, Mäder K. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev, 47:165-196. (Pubitemid 32324113)
20. Seyfoddin A, Shaw J, Al-Kassas R. (2010). Solid lipid nanoparticles for ocular drug delivery. Drug Deliv, 17:467-489.
21. Kaur IP, Kanwar M. (2002). Ocular preparations: the formulation approach. Drug Dev Ind Pharm, 28:473-493. (Pubitemid 34680549)
22. Kaur IP, Rana C, Singh H. (2008). Development of efective ocular preparations of antifungal agents. J Ocul Pharmacol Ter, 24:481-493.
23. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone M F. (2002). Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm, 238:241-245. (Pubitemid 34457892)
24. Almeida A J, Runge S, Müller RH. (1997) Peptide-loaded solid lipid nanoparticles (SLN): Infuence of production parameters, Int J Pharm, 149: 255-265. (Pubitemid 27193412)
25. Attama AA, Müller-Goymann CC. (2007). Investigation of surface-modifed solid lipid nanocontainers formulated with a heterolipid-templated homolipid. Int J Pharm, 334:179-189. (Pubitemid 46400318)
26. Nie. X, LiKong J, Li N, Ju C y, Pan WS. (2008) A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm, 363: 177-182.
27. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. (2005). Preparation and characterization of stearic acid nanostructured lipid carriers by solvent difusion method in an aqueous system. Colloids Surf B Biointerfaces, 45:167-173. (Pubitemid 41415646)
28. Shen J, Sun M, Ping Q, Ying Z, Liu W. (2010) Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement, Nanotech, 21: 1-10.
29. Vighi E, Ruozi B, Montanari M, Battini R, Leo E. (2007). Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid. Eur J Pharm Biopharm, 67:320-328. (Pubitemid 47211893)
30. Heydenreich AV, Westmeier R, Pedersen N, Poulsen HS, Kristensen HG. (2003). Preparation and purifcation of cationic solid lipid nanospheres-efects on particle size, physical stability and cell toxicity. Int J Pharm, 254:83-87. (Pubitemid 36259816)
31. Fang JY, Fang CL, Liu CH, Su YH. (2008). Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm, 70:633-640.
32. Li R, Jiang S, Liu D, Bi X, Wang F, Zhang Q, Xu Q, (2010) A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide, J Microencapsul, 1-8.
33. Liu Z, Zhang X, Wu H, Li J, Shu L, Liu R et al. (2011). Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Dev Ind Pharm, 37:475-481.
34. Saettone M F, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L. (1996) Evaluation of ocular permeation enhancers: In vitro efects on corneal transport of four [beta]-blockers, and in vitro/in vivo toxic activity. Int J Pharm, 142: 103-113. (Pubitemid 26343835)
35. Monti D, Chetoni P, Burgalassi S, Najarro M, Saettone MF. (2002). Increased corneal hydration induced by potential ocular penetration enhancers: assessment by diferential scanning calorimetry (DSC) and by desiccation. Int J Pharm, 232:139-147. (Pubitemid 34076759)
36. Schoenwald RD, Huang HS. (1983). Corneal penetration behavior of beta-blocking agents I: Physiochemical factors. J Pharm Sci, 72:1266-1272. (Pubitemid 14229733)
37. Sinha VR, Trehan A, Kumar M, Singh S, Bhinge Jr. (2007). Stress studies on acyclovir. J Chromatogr Sci, 45:319-324. (Pubitemid 47025393)
38. Lv Q, Yu A, Xi Y, Li H, Song Z, Cui J et al. (2009). Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm, 372:191-198.
39. Trotta M, Debernardi F, Caputo O. (2003). Preparation of solid lipid nanoparticles by a solvent emulsifcation-difusion technique. Int J Pharm, 257:153-160. (Pubitemid 36507041)
40. Subedi RK, Kang KW, Choi HK. (2009). Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci, 37:508-513.
41. Attia A. (2005) Why should researchers report the confdence interval in modern research?, Mid East Ferti Soci J, 10: 78-81. (Pubitemid 40559472)
42. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. (2007). Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm, 328:191-195. (Pubitemid 44880576)
43. Abdalla A, Mäder K. (2007). Preparation and characterization of a self-emulsifying pellet formulation. Eur J Pharm Biopharm, 66:220-226. (Pubitemid 46654779)
44. Swart KJ, Hundt HK, Groenewald AM. (1994). Automated high-performance liquid chromatographic method for the determination of acyclovir in plasma. J Chromatogr A, 663:65-69. (Pubitemid 24075211)
45. Souto EB, Mehnert W, Müller RH. (2006). Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J Microencapsul, 23:417-433. (Pubitemid 44132550)
46. Gokce EH, Sandri G, Bonferoni MC, Rossi S, Ferrari F, Güneri T et al. (2008). Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm, 364:76-86.
47. Gökçe EH, Sandri G, Egrilmez S, Bonferoni MC, Güneri T, Caramella C. (2009). Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. Curr Eye Res, 34:996-1003.
48. zur Mühlen A, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm, 45:149-155. (Pubitemid 28167741)
49. Schwarz C, Mehnert W. (1999). Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul, 16:205-213. (Pubitemid 29099602)
50. Freitas C, Müllerä RH. (1998). Spray-drying of solid lipid nanoparticles (SLN TM). Eur J Pharm Biopharm, 46:145-151. (Pubitemid 28414472)
51. Freitas C, Müller RH. (1999). Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm, 47:125-132. (Pubitemid 29185115)
52. Jenning V, Mäder K, Gohla SH. (2000). Solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids: a (1) H-NMR study. Int J Pharm, 205:15-21.
53. Alex A, Paul W, Chacko A, Sharma C P. (2011) Enhanced delivery of lopinavir to the CNS using Compritol®-based solid lipid nanoparticles, Terap Del, 2: 25-35.
54. Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N et al. (2009). Efect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine, 5:184-191.
55. Helgason T, Awad TS, Kristbergsson K, McClements DJ, Weiss J. (2009). Efect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN). J Colloid Interface Sci, 334:75-81.
56. Radomska-Soukharev A. (2007). Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev, 59:411-418. (Pubitemid 47259223)
57. Westesen K, Siekmann B, (1997)Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles, Int J Pharm, 151: 35-45. (Pubitemid 27212302)
58. Lukowski G, Werner U, (1998) Investigation of surface and drug release of solid lipid nanoparticles loaded with aciclovir, 425-426.
59. Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm, 50:161-177. (Pubitemid 30326695)
60. Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mäder K. (2004). Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, feld-fow fractionation and transmission electron microscopy. J Control Release, 95:217-227. (Pubitemid 38230037)
61. Gwak HS, Chun IK. (2002). Efect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. Int J Pharm, 236:57-64. (Pubitemid 34219373)
62. Borhade V, Nair H, Hegde D. (2008). Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS PharmSciTech, 9:13-21.
63. Schwarz C, Mehnert W. (1997). Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm, 157:171-179. (Pubitemid 27471169)
64. del Pozo-Rodríguez A, Solinís MA, Gascón AR, Pedraz JL. (2009). Short-and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur J Pharm Biopharm, 71:181-189.
65. Liu Z, Pan W, Nie S, Zhang L, Yang X, Li J. (2005). Preparation and evaluation of sustained ophthalmic gel of enoxacin. Drug Dev Ind Pharm, 31:969-975. (Pubitemid 41759208)
66. Saettone M F, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L. (1996) Evaluation of ocular permeation enhancers: In vitro efects on corneal transport of four β-blockers, and in vitro/in vivo toxic activity, Int J Pharm, 142: 103-113. (Pubitemid 26343835)
67. Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, Singh M. (2010). Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release, 144:233-241.
68. Morissette SL, Almarsson O, Peterson ML, Remenar JF, Read MJ, Lemmo AV et al. (2004). High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev, 56:275-300. (Pubitemid 38201426)
69. Corrigan DO, Healy AM, Corrigan OI. (2003). Te efect of spray drying solutions of bendrofumethiazide/polyethylene glycol on the physicochemical properties of the resultant materials. Int J Pharm, 262:125-137. (Pubitemid 36966700)
70. Shen J, Sun M, Ping Q, Ying Z, Liu W. (2010). Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology, 21:025101.
71. Abdelkader H, Ismail S, Kamal A, Alany RG. (2011). Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery. J Pharm Sci, 100:1833-1846.